Results 231 to 240 of about 94,246 (299)

Managing Nonalcoholic Fatty Liver Disease Through Structured Lifestyle Modification Interventions. [PDF]

Am J Lifestyle Med
Thomas A, Thomas A.
europepmc   +1 more source

Chrysin Exhibits Bone‐Protective Effects Through Osteoclastogenesis Inhibition: In Vitro and In Vivo Evaluation in RAW 264.7 Murine Macrophages and Sprague–Dawley Rats

Molecular Nutrition &Food Research, Volume 70, Issue 3, 13 February 2026.
The effects of chrysin, a plant‐derived compound, were investigated on osteoclast formation in cell culture and bone health parameters in Sprague–Dawley rats. Chrysin was shown to disrupt key osteoclast signaling pathways and inhibit osteoclast formation. Furthermore, chrysin moderately improved bone health parameters in the rats.
Caitlin Mason, Trevor T. Nyakudya, Abe E. Kasonga   +2 more
wiley   +1 more source

Corrigendum to "Bone Turnover Markers in Adults with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis". [PDF]

Int J Endocrinol
europepmc   +1 more source

Causal Relationship Between Genetically Determined Free Fatty Acids and Nonalcoholic Fatty Liver Disease: A Mendelian Randomization Study. [PDF]

Int J Endocrinol
Li K, Liang Y, Zhang X, Hu P, Hu M.
europepmc   +1 more source

Examining Biomarkers for Dyslipidemia, Diabetes, and NAFLD by CDC's 2022 Extended BMI Percentiles in US Youth Aged 6–17 Years

Obesity, Volume 34, Issue 2, Page 450-459, February 2026.
ABSTRACT Objective This study examined associations between CDC's 2022 extended BMI percentiles (BMIp) and cardiometabolic biomarkers. Methods Using electronic medical record data, we included patients aged 6–17 years with BMI ≥ 85th percentile who had at least one of the following: total cholesterol, low‐density lipoprotein cholesterol (LDL), high ...
Samantha L. Pierce, Renee M. Porter, Lyudmyla Kompaniyets, Siran He, Alyson B. Goodman   +4 more
wiley   +1 more source

Association Between Chitinase 3-Like Protein 1 and Severe Nonalcoholic Fatty Liver Disease: A Large Prospective Cohort Study in UK Biobank. [PDF]

Clin Transl Gastroenterol
Zou J, Yan Y, Liu A, Zhang H, Liu Z.
europepmc   +1 more source

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

Comparative mortality outcomes in metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease subtypes in the United States. [PDF]

PLoS One
Zhang P, Yang S, Hu R, Peng T, Yu P, Zeng Y, Ye C, Wang P, Dong X, Che Z.   +9 more
europepmc   +1 more source

Hevin Promotes Aging‐Related Cardiac Dysfunction via Facilitating Cardiac Inflammation in Male Mice

Aging Cell, Volume 25, Issue 2, February 2026.
Hevin released by iWAT into circulation stimulates cardiac macrophages through TLR4, inducing their polarization and CCL5 secretion, leading to worsened cardiac dysfunction and subsequent recruitment of additional inflammatory cells for pro‐inflammatory factor release.
Shi‐Yu Huang, Yu‐Jie Chen, Yu‐Xin Hu, Jia‐Chen Liu, Min Hu   +4 more
wiley   +1 more source